guest ::
| Home > Publications database > Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI > print |
| Home > Publications database > Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI > print |
| 001 | 874903 | ||
| 005 | 20230217124536.0 | ||
| 024 | 7 | _ | |a 10.1093/noajnl/vdz038 |2 doi |
| 024 | 7 | _ | |a 2128/24699 |2 Handle |
| 024 | 7 | _ | |a pmid:32642667 |2 pmid |
| 024 | 7 | _ | |a WOS:000886002700031 |2 WOS |
| 037 | _ | _ | |a FZJ-2020-01691 |
| 100 | 1 | _ | |a Galldiks, Norbert |0 P:(DE-Juel1)143792 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Imaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI |
| 260 | _ | _ | |a Oxford |c 2019 |b Oxford University Press |
| 264 | _ | 1 | |3 online |2 Crossref |b Oxford University Press (OUP) |c 2019-10-20 |
| 264 | _ | 1 | |3 print |2 Crossref |b Oxford University Press (OUP) |c 2019-05-01 |
| 264 | _ | 1 | |3 print |2 Crossref |b Oxford University Press (OUP) |c 2019-05-01 |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1587470944_11511 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a The prospective REGOMA phase 2 trial showed an encouraging and significant median progression-free and overall survival (PFS, OS) benefit for glioblastoma patients at first progression treated with the oral multikinase inhibitor regorafenib compared to lomustine monotherapy.1 In particular, the OS benefit was 1.8 months compared to lomustine (7.4 vs. 5.6 months; P = .0009), and the hazard ratio was 0.5 (95% confidence interval, 0.33–0.75). Interestingly, despite unchanged MRI findings at first follow-up (“Stable Disease,” 39%) following regorafenib, complete or partial radiological responses according to the RANO criteria2 were only seen in 5% of cases treated with regorafenib. On the other hand, 59% of patients in the regorafenib arm had grade 3–4 adverse events. |
| 536 | _ | _ | |a 572 - (Dys-)function and Plasticity (POF3-572) |0 G:(DE-HGF)POF3-572 |c POF3-572 |f POF III |x 0 |
| 542 | _ | _ | |i 2019-10-20 |2 Crossref |u http://creativecommons.org/licenses/by-nc/4.0/ |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Werner, Jan-Michael |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Tscherpel, Caroline |0 P:(DE-Juel1)168559 |b 2 |
| 700 | 1 | _ | |a Fink, Gereon R |0 P:(DE-Juel1)131720 |b 3 |
| 700 | 1 | _ | |a Langen, Karl-Josef |0 P:(DE-Juel1)131777 |b 4 |
| 773 | 1 | 8 | |a 10.1093/noajnl/vdz038 |b Oxford University Press (OUP) |d 2019-05-01 |n 1 |3 journal-article |2 Crossref |t Neuro-Oncology Advances |v 1 |y 2019 |x 2632-2498 |
| 773 | _ | _ | |a 10.1093/noajnl/vdz038 |g p. vdz038 |0 PERI:(DE-600)3009682-0 |n 1 |p vdz038 |t Neuro-oncology advances |v 1 |y 2019 |x 2632-2498 |
| 856 | 4 | _ | |y OpenAccess |u https://juser.fz-juelich.de/record/874903/files/vdz038.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://juser.fz-juelich.de/record/874903/files/vdz038.pdf?subformat=pdfa |
| 909 | C | O | |o oai:juser.fz-juelich.de:874903 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)143792 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131777 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-572 |2 G:(DE-HGF)POF3-500 |v (Dys-)function and Plasticity |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | 1 | _ | |a FullTexts |
| 999 | C | 5 | |a 10.1016/S1470-2045(18)30675-2 |9 -- missing cx lookup -- |1 Lombardi |p 110 - |2 Crossref |t Lancet Oncol. |v 20 |y 2019 |
| 999 | C | 5 | |a 10.1200/JCO.2009.26.3541 |9 -- missing cx lookup -- |1 Wen |p 1963 - |2 Crossref |t J Clin Oncol. |v 28 |y 2010 |
| 999 | C | 5 | |a 10.1093/neuonc/noz071 |1 Tzaridis |y 2019 |2 Crossref |t Neuro Oncol |9 -- missing cx lookup -- |
| 999 | C | 5 | |a 10.1007/s00432-019-02868-5 |9 -- missing cx lookup -- |1 Kebir |p 1037 - |2 Crossref |t J Cancer Res Clin Oncol. |v 145 |y 2019 |
| 999 | C | 5 | |a 10.1093/neuonc/now058 |9 -- missing cx lookup -- |1 Albert |p 1199 - |2 Crossref |t Neuro Oncol. |v 18 |y 2016 |
| 999 | C | 5 | |a 10.1038/nrneurol.2017.44 |9 -- missing cx lookup -- |1 Langen |p 279 - |2 Crossref |t Nat Rev Neurol. |v 13 |y 2017 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|